Last reviewed · How we verify
Irinotecan, 5FU, leucovorin
This combination chemotherapy regimen inhibits DNA synthesis and cell division through topoisomerase I inhibition and fluoropyrimidine-mediated nucleotide antagonism.
This combination chemotherapy regimen inhibits DNA synthesis and cell division through topoisomerase I inhibition and fluoropyrimidine-mediated nucleotide antagonism. Used for Metastatic colorectal cancer, Advanced gastric cancer, Pancreatic cancer.
At a glance
| Generic name | Irinotecan, 5FU, leucovorin |
|---|---|
| Also known as | CAMPTO (CAMPOSAR) |
| Sponsor | Asan Medical Center |
| Drug class | Chemotherapy combination (topoisomerase I inhibitor + antimetabolite) |
| Target | Topoisomerase I; thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Irinotecan is a topoisomerase I inhibitor that prevents DNA religation, leading to DNA damage and cell death. 5-Fluorouracil (5FU) is a nucleotide analog that inhibits thymidylate synthase and incorporates into RNA/DNA, disrupting synthesis. Leucovorin (folinic acid) enhances 5FU efficacy by stabilizing the 5FU-thymidylate synthase complex, increasing cytotoxicity.
Approved indications
- Metastatic colorectal cancer
- Advanced gastric cancer
- Pancreatic cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Anemia
- Mucositis
- Fatigue
- Alopecia
Key clinical trials
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (PHASE3)
- Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer (PHASE2)
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Irinotecan, 5FU, leucovorin CI brief — competitive landscape report
- Irinotecan, 5FU, leucovorin updates RSS · CI watch RSS
- Asan Medical Center portfolio CI